NOT JUST ANY SOLUTION
OXERVATE® is the only FDA-approved treatment option that targets the underlying cause of NK to enable complete corneal healing in most patients.*1-6
The most common adverse reaction reported in clinical trials (~16%) was eye pain following instillation.1
Resolution was evaluated in clinical trials as complete corneal healing, defined as the absence of staining in the lesion area and no persistent staining in the rest of the cornea after 8 weeks of treatment and as <0.5-mm lesion staining at 48-week follow-up.1,4,5
NK is caused by corneal nerve damage6
Corneal nerve damage may lead to a decrease in or total loss of corneal sensitivity—the hallmark of neurotrophic keratitis (NK).7
NK is a progressive condition and is classified into 3 stages of increasing severity (based on the Mackie classification). If left untreated, NK can lead to severe corneal damage.2,7
A unique mechanism of action that targets corneal nerve damage, the underlying cause of NK1-3,6
Cenegermin-bkbj, the active ingredient in OXERVATE, is a recombinant form of human nerve growth factor (NGF) that supports corneal innervation and integrity.1-3,6,7
Efficacy & Safety
The efficacy and safety of OXERVATE® were established in the largest clinical trial program conducted in patients with NK1
In clinical trials, up to
of patients achieved complete corneal healing at week 8
with a single course of therapy*†1
Of these patients, (REPARO trial)
at 1 year†8
Key study findings were after 8 weeks of treatment, 6 times daily. REPARO (Study NGF0212): 52 European patients with neurotrophic keratitis (NK) in 1 eye per group; 72% of patients completely healed; vehicle response rate 33.3%. Study NGF0214: 24 US patients with NK in 1 or both eyes per group; 65.2% completely healed; vehicle response rate 16.7%.4,5
Complete corneal healing was defined as the absence of staining in the lesion area and no persistent staining in the rest of the cornea after 8 weeks of treatment and as <0.5-mm lesion staining at 48-week follow-up.4,5
In clinical trials, OXERVATE was generally well tolerated1
The most common adverse reaction was eye pain following instillation, which was reported in approximately 16% of patients.
Other adverse reactions occurring in 1%-10% of patients taking OXERVATE, and more frequently than in the vehicle-treated patients, included corneal deposits, foreign body sensation, ocular hyperemia, ocular inflammation, and tearing.
Access support and more through a single point of contact
Dompé CONNECT to Care provides practices and patients with assistance every step of the way.